Clinical trial
A Phase 1/2, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
NCT00841191 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
- Lead sponsor
- Centocor, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2009
- Completion date
- April 30, 2011
- Enrollment
- 84 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.